Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites.
In 23 patients treated with the iodine-containing antiarrhythmic drug amiodarone, the plasma concentrations of amiodarone, desethylamiodarone and iodine have been studied. Besides amiodarone and desethylamiodarone, a pool of iodine-containing substances, NANDAI (non-amiodarone-, non-desethylamiodarone-iodine), was present. At steady state the iodine content of NANDAI amounted to 64% and the iodine content of amiodarone plus desethylamiodarone to 36% of total serum iodine. At steady state 26% of the NANDAI fraction was made up of inorganic iodide, the average plasma concentration of which was at least 40 times above the upper limit of the normal range. The serum elimination half-life of NANDAI of 57-160 days exceeded that of amiodarone (35-68 days) and of desethylamiodarone (31-110 days). At steady state the serum concentration of desethylamiodarone appears to be related to the concentration of amiodarone by a Michaelis-Menten type function, yielding a Km of amiodarone of 2.45 mumol/l and a maximal desethylamiodarone concentration of 3.61 mumol/l.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism* / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001572:Benzofurans / Q000378:metabolism*; D005260:Female; D006207:Half-Life; D006801:Humans; D007454:Iodides / Q000378:metabolism; D007455:Iodine / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D001572:Benzofurans; D007454:Iodides; D007455:Iodine; C036116:desethylamiodarone; D000638:Amiodarone